Jazz Pharmaceuticals

Earlier this month, we attended the 9th Lennox-Gastaut Syndrome (LGS) Foundation Family and Professional Conference to connect with members of the Lennox-Gastaut syndrome (LGS) community and #epilepsy professionals from around the world. We are inspired by the strength and resilience of the LGS community and are committed to pursuing research approaches that address rare epilepsy syndromes.

In our continued efforts to prioritize corporate sustainability and social impact, our legal team members Sasha Willmott and Brian Clot recently participated pro bono in the Bright Tide’s Regenerative Farming accelerator program hosted by Hogan Lovells - HL BaSE. Teams were able to advise alongside fellow legal professionals on 9 different ventures – each one addressing sustainability and biodiversity loss. We are so proud that our team was able to contribute to making a difference for local communities and our environment. Read more about this pro-bono workshop: https://bit.ly/3WzCaP4

We’re pleased to welcome a new independent director, Laura Hamill, to the Jazz Board of Directors. Learn more: https://lnkd.in/eBDRrCPb

At Jazz, creating a great work experience for employees allows us to better serve our patients. Our EVP and Chief People Officer Heidi Manna spoke to David Green 🇺🇦 on the #DigitalHRLeaders podcast about the employee experience at Jazz and what makes us so unique, including our flexible working model, Jazz Remix. Heidi shared four elements of our people strategy and talked about the importance of really listening to employees, including how continuous dialogue helps to shape our working policies. https://lnkd.in/eBxWFHRJ #GreatPlacetoWork

#WorldBrainDay serves as a rallying point to increase education and advocacy efforts to help ensure that every individual has the knowledge and resources to prioritize and maintain their brain health. Today, we join the World Federation of Neurology and our global communities in the effort to champion quality neurology and promote brain health for all.   Through strategic global advocacy partnerships, we continuously strive to better our understanding of patients’ needs in order to advance research around complex neurological disorders and develop medicines that are truly meaningful for people living with these conditions.   By spreading awareness and fostering collaborations, we can collectively pave the way for a healthier future for those impacted.

We’re pleased to announce that Samantha Pearce, Senior Vice President, Europe and International, has been promoted to Chief Commercial Officer effective August 1, 2024. With over 30 years of commercial experience in the pharmaceutical industry, Sam is an inspiring leader who will help us to drive continued transformational growth for our global commercial business in support of our mission to deliver pioneering medicines for people living with serious diseases.

Our 2023 Corporate Sustainability and Social Impact (CSSI) Report is now live here: https://bit.ly/3zmqaqZ    Our values anchor our corporate strategy and support our commitment to generating positive outcomes for patients, employees and other stakeholders. In 2023, we emphasized strengthening the governance of our CSSI strategy to ensure we can deliver positive impact across our key pillars.    We will continue to strive for sustainable growth and enhanced value while focusing on reducing our environmental footprint and furthering our capabilities as a responsible and innovative biopharmaceutical company.

Now Live: Explore our revamped careers website and discover exciting opportunities to join our team! We've updated the experience to make it easier than ever to learn about working at Jazz and find your next career opportunity.    Visit the new site at https://lnkd.in/gYBrm6SW

We’re at the 2024 ESMO - European Society for Medical Oncology Gastrointestinal Cancers Congress to present our latest data and contribute to greater understanding of difficult-to-treat #GastrointestinalCancers, such as biliary tract cancer (BTC). Although BTC accounts for less than 1% of all adult cancers, an estimated 35,000 people are diagnosed in Europe every year. Hear from our VP of Medical Affairs Europe & International, Tomas Skacel, on the need for greater awareness and early recognition of BTC, and for healthcare professionals onsite at #ESMOGI24 this week, visit us at booth #31.

Today, on International #DravetAwarenessDay, we are supporting charities, families and organizations around the world in raising awareness of #DravetSyndrome (DS). DS is a rare, severe and lifelong form of epilepsy that usually begins in the first year of life and leads to some level of developmental disability and dependency on caregivers. Isabella Brambilla, Chairperson of Dravet Italia Onlus, discusses the broader impact of DS on family life, drawing on her own experience caring for her son, who lives with the condition. Your local Dravet Syndrome foundation, such as Dravet Italia Onlus, is a great place to go to access resources for those living with DS, or visit the Dravet Syndrome Foundation.